Funding for this research was provided by:
research funds from the Division of Rheumatology at the University of Alabama at Birmingham (No number)
resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA (No number)
Text and Data Mining valid from 2019-03-15
Received: 20 March 2018
Accepted: 3 March 2019
First Online: 15 March 2019
Ethics approval and consent to participate
: The University of Alabama at Birmingham’s Institutional Review Board approved this study and all investigations were conducted in conformity with ethical principles of research. The IRB waived the need for an informed consent for this database study.
: Not required.
: JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Fidia, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC, National Institute of Health and the American College of Rheumatology. JAS owns stock options in Amarin pharmaceuticals and Viking therapeutics. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c)(3) entity. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JDC has no relevant financial conflicts. There are no non-financial competing interests for either author.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.